nach oben

best practice onkologie

Erschienen in:

23.05.2019 | Basalzellkarzinom | CME

Fortgeschrittene Basalzell- und Plattenepithelkarzinome der Haut

Aktuelle systemische Therapieoptionen

verfasst von: Prof. Dr. T. Gambichler, Dr. L. Susok

Erschienen in: best practice onkologie | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Nach dem Melanom ist das kutane Plattenepithelkarzinom („cutaneous squamous cell carcinoma“ [cSCC]) der am zweithäufigsten zum Tode führende Hauttumor. Ende 2017 wurden für das fortgeschrittene cSCC positive Ergebnisse zum Immuncheckpointinhibitor Cemiplimab berichtet, einem humanen, monoklonalen Antikörper gegen das Protein PD-1 („programmed death 1“). Aber auch für die primär gegen das Melanom eingesetzten PD-1-Blocker (Pembrolizumab, Nivolumab) gibt es inzwischen überzeugende Daten für die systemische cSCC-Behandlung. Das Basalzellkarzinom (BCC) ist bei Kaukasiern der häufigste Hautkrebs, der zwar selten metastasiert, aber häufiger lokal inoperabel ist. Mit der im Jahr 2012 bzw. 2015 erfolgten Zulassung der Hedgehog-Inhibitoren Vismodegib und Sonidegib besteht nun die Möglichkeit, bei metastasiertem oder inoperablem BCC eine wirkungsvolle orale zielgerichtete Systemtherapie einzusetzen. Zu den Immuncheckpointblockern beim BCC gibt es ebenfalls erste vielversprechende Daten.

Koelblinger P, Lang R (2018) New developments in the treatment of basal cell carcinoma: Update on current and emerging treatment options with a focus on vismodegib. Onco Targets Ther 11:8327–8340PubMedPubMedCentralCrossRef

Lang et al (2018) Basalzellkarzinom der Haut. https://www.awmf.org/leitlinien/detail/ll/032-021.html . Zugegriffen: 21. Januar 2019

Waldman A, Schmults C (2019) Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am 33(1):1–12PubMedCrossRef

Siegel R et al (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387 PubMedCrossRef

Burton KA et al (2016) Cutaneous squamous cell carcinoma: A review of high-risk and metastatic disease. Am J Clin Dermatol 17:491–508. https://doi.org/10.1007/s40257-016-0207 PubMedCrossRef

Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin V, Kessler M, Serra A, Hofbauer G, Pouteil-Noble C, Campistol J, Kanitakis J, Roux A, Decullier E, Dantal J et al (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339PubMedCrossRef

Parikh SA, Patel VA, Raatner D (2014) Advances in the management of cutaneous squamous cell carcinoma. F1000prime Rep 6:70PubMedPubMedCentralCrossRef

Murad A, Ratner D (2001) Cutaneous squamous-cell carcinoma. N Engl J Med 344(13):975–983CrossRef

Breuninger et al (2013) Plattenepithelkarzinom der Haut. https://www.awmf.org/leitlinien/detail/ll/032-022.html . Zugegriffen: 22. Januar 2019

10.

Apalla Z, Lallas A, Sotiriou E et al (2017) Epidemiological trends in skin cancer. Dermatol Pract Concept 7(2):1–6PubMedPubMedCentralCrossRef

11.

Lomas A, Bee-Leonardi J, Bath-Hextall F (2012) A systematic review of worldwide incidence of non-melanoma skin cancer. Br J Dermatol 166:1069–1080PubMedCrossRef

12.

Stratigos A, Garbe C, Lebbe C et al (2015) Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 51(14):1989–2007PubMedCrossRef

13.

Berliner JG, Schulman JM, Lazarova Z et al (2019) Response of cutaneous squamous cell carcinoma to treatment with cetuximab. Dermatol Surg 45(2):313–316PubMedCrossRef

14.

Maubec E, Petrow P, Scheer-Senyarich I et al (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29(25):3419PubMedCrossRef

15.

Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quéreux G, Dreno B (2014) Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat 25(5):424–427PubMedCrossRef

16.

Samstein RM, Ho AL, Lee NY, Barker CA (2014) Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy. J Skin Cancer. https://doi.org/10.1155/2014/284582 PubMedPubMedCentralCrossRef

17.

Dereure O, Missan H, Girard C, Costes V, Guillot B (2016) Efficacy and tolerance of cetuximab alone or combined with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinoma: An open study of 14 patients. Dermatology 232(6):721–730PubMedCrossRef

18.

Sadreddini S, Baradaran B, Aghebati-Maleki A, Sadreddini S, Shanehbandi D, Fotouhi A, Aghebati-Maleki L (2018) Immune checkpoint blockade opens a new way to cancer immunotherapy. J Cell Physiol 234(6):8541–8549. https://doi.org/10.1002/jcp.27816 PubMedCrossRef

19.

Borradori L, Sutton B, Shayesteh P, Daniels GA (2016) Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: Preliminary experience in five cases. Br J Dermatol 175(6):1382–1386PubMedCrossRef

20.

Chang AL, Kim J, Luciano R, Sullivan-Chang L, Colevas AD (2016) A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 Inhibitor. JAMA Dermatol 152(1):106–108PubMedCrossRef

21.

Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Fröhling S, Penzel R, Enk A, Hassel JC (2017) Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol 176(2):498–502PubMedCrossRef

22.

Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, Pavlick AC, Carucci JA (2017) Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol 153(4):299–303PubMedCrossRef

23.

Degache E, Crochet J, Simon N, Tardieu M, Trabelsi S, Moncourier M, Templier I, Foroni L, Lemoigne A, Pinel N, Gil H, Bouillet L, Leccia MT, Charles J (2018) Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol 32(7):e257–e258PubMedCrossRef

24.

Blum V, Müller B, Hofer S, Pardo E, Zeidler K, Diebold J, Strobel K, Brand C, Aebi S, Gautschi O (2018) Nivolumab for recurrent cutaneous squamous cell carcinoma: Three cases. Eur J Dermatol 28(1):78–81PubMed

25.

Midgen M, Rischin D, Schmults C, Guminski A, Hauschild A, Lewis K, Chung C, Hernandez-Aya L, Lim A, Chang A, Rabinowits G, Thai A, Dunn L, Hughes B, Khushalani N, Modi B, Schadendorf D, Gao B, Seebach F et al (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379:341–351CrossRef

26.

Hermel DJ, Ragab OM, Higgins S, Wysong A, In GK (2018) PD-1 inhibition in cutaneous squamous cell carcinoma (cSCC). J Clin Oncol 36(15_suppl):e15100–e15100CrossRef

27.

Maubec E, Boubaya M, Petrow P, Basset-Seguin N, Grob JJ et al (2018) Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial. J Clin Oncol 36(15_suppl):9534–9534CrossRef

28.

Kudchadkar RR, Yushak ML, Lawson DH, Delman KA, Lowe MC et al (2018) Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC). J Clin Oncol 36(15_suppl):9543–9543CrossRef

29.

Beasley GM, Kurtz J, Vandeusen J, Howard JH, Terando A, Agnese D et al (2017) Immune checkpoint inhibitor therapy as a novel and effective therapy for aggressive cutaneous squamous-cell carcinoma. Clin Skin Cancer 1(2):75–81CrossRef

30.

Frampton JE, Basset-Séguin N (2018) Vismodegib: A review in advanced basal cell carcinoma. Drugs 78(11):1145–1156PubMedCrossRef

31.

Tay EY, Teoh YL, Yeo MS (2018) Hedgehog pathway inhibitors and their utility in basal cell carcinoma: A comprehensive review of current evidence. Dermatol Ther (Heidelb). https://doi.org/10.1007/s13555-018-0277-7 CrossRef

32.

Xie P, Lefrançois P (2018) Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. J Am Acad Dermatol 79(6):1089–1100.e17PubMedCrossRef

33.

Chen L, Aria AB, Silapunt S, Lee HH, Migden MR (2018) Treatment of advanced basal cell carcinoma with sonidegib: Perspective from the 30-month update of the BOLT trial. Future Oncol 14(6):515–525PubMedCrossRef

34.

Lipson EJ, Lilo MT, Ogurtsova A, Esandrio J, Xu H, Brothers P, Schollenberger M, Sharfman WH, Taube JM (2017) Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer 5:23PubMedPubMedCentralCrossRef

35.

Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R (2016) Metastatic basal cell carcinoma with amplification of PD-L1: Exceptional response to anti-PD1 therapy. NPJ Genom Med 1:16037. https://doi.org/10.1038/npjgenmed.2016.37 PubMedPubMedCentralCrossRef

36.

Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG (2016) Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer 4:70PubMedPubMedCentralCrossRef

37.

Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R (2017) Appearance of new cutaneous superficial basal cell carcinomas during successful nivolumab treatment of refractory metastatic disease: Implications for immunotherapy in early versus late disease. Int J Mol Sci 18(8):E1663PubMedCrossRef

38.

Cannon JGD, Russell JS, Kim J, Chang ALS (2018) A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. JAAD Case Rep 4(3):248–250PubMedPubMedCentralCrossRef

39.

Fischer S, Ali OH, Jochum W, Kluckert T, Flatz L, Siano M (2018) Anti-PD-1 therapy leads to near-complete remission in a patient with metastatic basal cell carcinoma. Oncol Res Treat 41(6):391–394PubMedCrossRef

40.

Chang ALS, Tran DC, Cannon JGD, Li S, Jeng M, Patel R, Van der Bokke L, Pague A, Brotherton R, Rieger KE, Satpathy AT, Yost KE, Reddy S, Sarin K, Colevas AD (2018) Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. J Am Acad Dermatol 80(2):564–566PubMedCrossRefPubMedCentral

Titel: Fortgeschrittene Basalzell- und Plattenepithelkarzinome der Haut
Aktuelle systemische Therapieoptionen
verfasst von: Prof. Dr. T. Gambichler
Dr. L. Susok
Publikationsdatum: 23.05.2019
Verlag: Springer Medizin
Schlagwörter: Basalzellkarzinom
Plattenepithelkarzinom der Haut
Basalzellkarzinom
Plattenepithelkarzinom der Haut
Basalzellkarzinom
Cetuximab
Basalzellkarzinom
Checkpoint-Inhibitoren
Checkpoint-Inhibitoren
Erschienen in: best practice onkologie / Ausgabe 6/2019
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI: https://doi.org/10.1007/s11654-019-0144-8

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Editorial

onko-aktuell

Erklärung zu finanziellen und nichtfinanziellen Interessen in CME-Fortbildungen von Springer Medizin

Bescheinigungen

Krebstherapie: Bei Polymedikation den Überblick behalten

Brustkrebs und schwanger – sinnvolle und kontraindizierte Therapien